Brief: Anixa Biosciences Announces Patient Dosing Of Its Investigational Vaccine Candidate In A First-Of-Its-Kind Preventative Breast Cancer Vaccine Study
26/10/2021 13:38
Oct 26 (Reuters) - Anixa Biosciences Inc ANIX.O :
* ANIXA BIOSCIENCES ANNOUNCES PATIENT DOSING OF ITS
INVESTIGATIONAL VACCINE CANDIDATE IN A FIRST-OF-ITS-KIND
PREVENTATIVE BREAST CANCER VACCINE STUDY
Source text for Eikon: ID:nPn1kSMV9a
Further company coverage: ANIX.O
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine